Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini.
2016
RS431.A64
Formats
| Format | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Linked e-resources
Details
Title
Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini.
Author
ISBN
9781617052521 (electronic bk.)
1617052523 (electronic bk.)
9781620700761
162070076X
9781620700761
1617052523 (electronic bk.)
9781620700761
162070076X
9781620700761
Published
New York : Demos Medical, [2016]
Language
English
Description
1 online resource (xiv, 189 pages) : color illustrations
Call Number
RS431.A64
System Control No.
(OCoLC)942588609
Summary
Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review . The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeuticómaking this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike. Key Features: Conveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction. Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes.
Note
Includes index.
Formatted Contents Note
Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites
AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies
Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index
AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies
Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index
Source of Description
Online resource; title from PDF title page (EBSCO, viewed March 8, 2016).
Available in Other Form
Print version: Worden, Francis P., MD. Cancer Pharmacology and Pharmacotherapy Review : Study Guide for Oncology Boards and MOC Exams. : Springer Publishing Company, ©2016
Linked Resources
Record Appears in